Published in final edited form as:

Bioorg Med Chem Lett. 2010 October 15; 20(20): 5994–5996. doi:10.1016/j.bmcl.2010.08.080.

Design and Synthesis of Substrates for Newborn Screening of Maroteaux-Lamy and Morquio A Syndromes

Trisha A. Duffey^{a,b}, Tanvir Khaliq^{a,b}, C. Ronald Scott^c, Frantisek Turecek^a, and Michael H. Gelb^{a,d}

^aDept of Chemistry, University of Washington, Seattle, WA 98195

^cDept of Medicine, University of Washington, Seattle, WA 98195

^dDept of Biochemistry, University of Washington, Seattle, WA 98195

Abstract

In continued efforts to develop enzymatic assays for lysosomal storage diseases appropriate for newborn screening laboratories we have synthesized novel and specific enzyme substrates for Maroteaux-Lamy (MPS VI) and Morquio A (MPS IVA) diseases. The sulfated monosaccharide derivatives were found to be converted to product by the respective enzyme in blood from healthy patients but not by blood from patients with the relevant lysosomal storage disease. The latter result shows that the designed substrates are highly selective for the respective enzymes.

The mucopolysaccharidoses (MPSs) are a class of lysosomal storage diseases caused by the deficiency in an enzyme in glycosaminoglycan catabolism. These syndromes result in non-degraded or partially degraded glycosaminoglycans amassing in the lysosome resulting in irreversible multisystemic organ damage 1–4. Recently, treatments have become available for some of the MPS syndromes; however optimal benefits from these treatments would require commencement of treatment prior to the onset of the irreversible symptoms. In continuance of our efforts on neonatal diagnosis of lysosomal storage diseases by tandem mass spectrometry^{5, 6}, we carried out the synthesis of two novel substrates that can be used to assay N-acetyl galactosamine 4-sulfatase, the enzyme deficient in Maroteaux-Lamy syndrome (MPS VI) and galactose 6-sulfatase, the enzyme deficient in Morquio A syndrome (MPS IVA)

The assays require substrates that are readily prepared, specific for the enzymes, and tagged for detection in the newborn screening laboratory. Natural substrates for the sulfatases are oligosaccharides containing a sulfate on the terminal sugar residue. While these oligosaccharides would be selective substrates for the enzymes, they are difficult to prepare on the scale needed for worldwide newborn screening (~10 g/year). In contrast, aryl sulfatases are readily available but show low specificity between the sulfatase enzymes. We based our substrate design on the terminal sugar of the natural substrates, i.e. N-acetylgalactosamine 4-sulfate and galactose 6-sulfate. The anomeric carbon of these sugars

© 2010 Elsevier Science Ltd. All rights reserved.

^bThese authors contributed equally to the manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary data

Experimental procedure for the synthesis and spectral data are available free of charge at www.sciencedirect.com.

were coupled to an umberferry moiety, which could be used for fluorescence assays in laboratories lacking tandem mass spectrometers. A carbon chain with a fragmentable *N-tert*-butyl carbamate was attached to direct the fragmentation of the parent ion in the mass spectrometer along a single reaction pathway, which increases the sensitivity of the tandem mass spectrometry assay. The linker chain lengths were chosen such that the mass of the products and internal standards do not coincide with the masses of any of the other neonatal assays developed earlier in our laboratory, thereby allowing the assays to be multiplexed in the mass spectrometry analysis.

The synthesis of both the compounds started with the amide coupling of 7-hydroxycoumarinyl-4-acetic acid with either mono-Boc protected 1,6-hexanediamine or 1,5-pentanediamine. The resulting substituted coumarins were glycosylated with two different glycosyl halide donors under phase transfer catalysis to afford the β -glycosides **7**. The acetate esters were then deprotected to afford glycosides **8**, **3**, **4**, and **10**. Glycosides **3** and **4** are the desired internal standards for the enzymatic assays and were used without further elaboration. The MPS IVA substrate **2** was readily synthesized from glycoside **10** by selective sulfation of the primary 6-hydroxyl group over the secondary 2, 3 and 4-hydroxyl groups as revealed by the downfield shift of H-6 in the sulfate relative to the non-sulfate **8**.

The MPS VI substrate (**1**) required further synthetic manipulations in order to install the sulfate at the more hindered 4-hydroxy of the sugar. Therefore, the less hindered 3- and 6-hydroxyls were selectively benzoylated to afford dibenzoate **9**. The glucosamine was then converted to a galactosamine by inversion of the 4-hydroxyl by formation of the triflate and displacement with sodium nitrite to afford **10**. Finally, sulfation of the free hydroxyl followed by cleavage of the benzoate protecting groups gave the desired MPS VI substrate (**1**).

Full synthetic details are provided as Supplementary data.

With the two substrates and two internal standards in hand, enzymatic activity was studied. The enzymatic activity was measured by incubating a solution of substrate and internal standard with a 2 mm diameter dried blood spot punch for 16 hr. The amount of product was quantified by tandem mass spectrometer using the internal standards. For MPS VI, the range of activity measured with 10 dried blood spots from healthy individuals was 1.6-10.5 $\mu\text{mol hr}^{-1}$ (L blood) $^{-1}$ compared to 0.08 $\mu\text{mol hr}^{-1}$ (L blood) $^{-1}$ using a dried blood spot from an MPS VI patient. For MPS IVA, the values are 0.021-0.35 $\mu\text{mol hr}^{-1}$ (L blood) $^{-1}$ for 30 dried blood spots from healthy patients and 0.00039-0.00043 $\mu\text{mol hr}^{-1}$ (L blood) $^{-1}$ from 6 patients with MPS IVA. These results serve to illustrate that the substrates are highly specific for the respective enzymes. Full details of the assay including assay statistics and performance on a large number of dried blood spots will be reported elsewhere.

In conclusion, we have synthesized substrates for two lysosomal sulfatases, N-acetylgalactosamine 4-sulfatase and galactose 6-sulfatase, they are highly specific for their respective enzymes. The syntheses developed can be readily scaled to prepare the ~10 g/yr of material needed to support worldwide newborn screening. Further evaluation of these reagents is under investigation in newborn screening laboratories.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Biomarin Pharmaceutical Inc. Novato CA and to the NIH (grant R01DK067859) for financial support.

References and notes

1. Dorfman A, Matalon R. Proc. Natl. Acad. Sci. U.S.A. 1976; 73:630–637. [PubMed: 813230]
2. Legum CP, Schorr S, Berman ER. Adv. Pediatr. 1976; 22:305–347. [PubMed: 131478]
3. Kresse H, Paschke E, Von Figura K, Gilberg W, Fuchs W. Proc. Natl. Acad. Sci. U.S.A. 1980; 77:6822–26.
4. Klein U, Kresse H, Von Figura K. Proc. Natl. Acad. Sci. U.S.A. 1978; 75:5185–89. [PubMed: 33384]
5. Wang D, Wood T, Sadilek M, Scott CR, Turecek F, Gelb MH. Clin. Chem. 2007; 53:1, 137. [PubMed: 17202494]
6. Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH. Clin. Chem. 2008; 54,:2067–70. [PubMed: 19042989]
7. Carriere D, Meunier SJ, Tropper FD, Cao S, Roy R. J. Mol. Cat. A: Chemical. 2000; 154:9–22.
8. Sawada T, Fujii S, Nakano H, Ohtake S, Kimata K, Habuchi O. Carbohydr. Res. 2005; 340:1983–96. [PubMed: 16024005]

Figure 1.
Maroteaux-Lamy substrate **1** and internal standard **3** and Morquio A substrate **2** and internal standard **4**.

Scheme 1.

Preparation of MPS-VI substrate **2** and internal standards **3** and **4**. Reagents and conditions:

(a) *N*-Boc-1,6-hexanediamine, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride, DMF, CH₂Cl₂, overnight, 52% (b) *N*-Boc-1,5-pentanediamine, *N*-(3-dimethylaminopropyl)-*N'*-ethylcarbodiimide hydrochloride, DMF, CH₂Cl₂, overnight, 62% (c) glycosyl chloride (**7a**, **7b**), peracetylated glycosyl bromide (**9**), tetrabutylammonium hydrogensulfate, aq. NaOH (1 M), DCM, 30-60 min (d) sodium methoxide, MeOH, CHCl₃, 4 h, **8** (from **6a** and **7a**) : 53% over two steps; **3** (from **6b** and **7b**) : 50% over two steps; **10** (from **6b** and **9**) : 28% over two steps, **4** (from **6a** and **9**) : 35% over two steps (e) sulfur trioxidepyridine complex, pyridine, 5 h; DOWEX 50WX8 (Na⁺ form), 45%.

Scheme 2.

Preparation of MPS-IVA substrate **1**. Reagents and conditions: (a) benzoyl chloride (2.1 equiv), pyridine, 0 °C, 3 h, 58% (b) triflic anhydride, pyridine, DCM, −20 °C, 3 h (c) sodium nitrite, DMF, overnight, 51% over two steps (d) sulfur trioxide-pyridine complex, pyridine, 3 h; DOWEX 50WX8 (Na⁺ form), 50% (e) sodium methoxide, MeOH, 5 d, 80%.